
FDA and DoD Work Together to Provide Medical Products to Military Personnel
The two agencies have launched a program to develop safe and effective medical products to be used by American military personnel.
On Jan. 16, 2018, FDA
The initial phase of the program will be conducted by FDA’s Center for Biologics Evaluation and Research (CBER) and Health Affairs, which will meet on a regular basis. Workshops will also be held to discuss scientific and clinical development of products. Current high-priority DoD product programs include freeze-dried plasma, cold-stored platelets, and cryopreserved platelets.
“This enhanced collaboration will enable the agency to gain a better understanding of the health needs of those protecting our country while ensuring that the medical products made available to our service members are safe and effective,” said Anna Abram, the FDA’s Deputy Commissioner for Policy, Planning, Legislation and Analysis, in a statement. “The initial program will ultimately allow us to implement a robust and enduring pathway across the entire agency to expedite access to such products as we fulfill our commitment to our Nation’s warfighters.”
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.